BSD Medical’s System Featured at Symposium on Hyperthermia for the Treatment of Cancer in Turkey

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the Company's BSD-2000-3D/MR System was featured at a symposium focused on the use of hyperthermia in the treatment of cancer held in Ankara, Turkey. The symposium, "MR Kontrollü Derin Bölgesel Hipertermi (MR controlled deep regional hyperthermia)," was hosted by Meyra Saglik, BSD’s distributor in Turkey, and chaired by Professor Dr. M. Kadri Altundag, MD, PhD, head of medical oncology department of Hacettepe University in Ankara.

Among the participants were senior officers of the Turkish Ministry of Health as well as key opinion leaders in the field of oncology in Turkey. The symposium was opened by a presentation from Professor Dr. Murat Gültekin, MD, Director of the Cancer Control Department at the Turkish Ministry of Health. His talk was followed by presentations from Dr. Jacoba van der Zee, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, and Assistant Professor Dr. Lars Lindner, MD, PhD, University of Munich Medical Center, Munich, Germany.

"We were very proud to host a successful symposium that included presentations from many prestigious speakers,” said Akif Unzuncarsili, CEO of Meyra Saglik. "We are looking forward to the first installation of a BSD hyperthermia system in Turkey.”

Turkey has a population of 80 million and is a strong market for medical device companies. The Turkish Ministry of Health has set up a program for improving the treatment of cancer in Turkey that includes investment in new technology.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.